For Novartis, 2012 Is Set To Be A Bumpy Ride
This article was originally published in The Pink Sheet Daily
Executive Summary
With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.
You may also be interested in...
Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella
Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.
Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets
Lundbeck becomes the latest company in Europe to announce job cuts, as austerity, generic competition and unclear pricing and reimbursement practices create uncertainties.
Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets
Lundbeck becomes the latest company in Europe to announce job cuts, as austerity, generic competition and unclear pricing and reimbursement practices create uncertainties.